Logo image of BNTX

BIONTECH SE-ADR (BNTX) Stock Fundamental Analysis

NASDAQ:BNTX - Nasdaq - US09075V1026 - ADR - Currency: USD

106.57  +1.65 (+1.57%)

After market: 106.57 0 (0%)

Fundamental Rating

3

Overall BNTX gets a fundamental rating of 3 out of 10. We evaluated BNTX against 557 industry peers in the Biotechnology industry. BNTX has only an average score on both its financial health and profitability. BNTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

BNTX had negative earnings in the past year.
In the past year BNTX had a positive cash flow from operations.
Of the past 5 years BNTX 4 years were profitable.
BNTX had a positive operating cash flow in 4 of the past 5 years.
BNTX Yearly Net Income VS EBIT VS OCF VS FCFBNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

With an excellent Return On Assets value of -2.95%, BNTX belongs to the best of the industry, outperforming 88.91% of the companies in the same industry.
BNTX has a Return On Equity of -3.43%. This is amongst the best in the industry. BNTX outperforms 90.70% of its industry peers.
Industry RankSector Rank
ROA -2.95%
ROE -3.43%
ROIC N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
BNTX Yearly ROA, ROE, ROICBNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

With an excellent Gross Margin value of 84.90%, BNTX belongs to the best of the industry, outperforming 88.19% of the companies in the same industry.
In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.
BNTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
BNTX Yearly Profit, Operating, Gross MarginsBNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BNTX has been increased compared to 5 years ago.
Compared to 1 year ago, BNTX has a worse debt to assets ratio.
BNTX Yearly Shares OutstandingBNTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BNTX Yearly Total Debt VS Total AssetsBNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

BNTX has an Altman-Z score of 6.29. This indicates that BNTX is financially healthy and has little risk of bankruptcy at the moment.
BNTX's Altman-Z score of 6.29 is amongst the best of the industry. BNTX outperforms 81.22% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that BNTX is not too dependend on debt financing.
BNTX has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.29
ROIC/WACCN/A
WACC7.13%
BNTX Yearly LT Debt VS Equity VS FCFBNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

BNTX has a Current Ratio of 7.45. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
BNTX has a better Current ratio (7.45) than 67.98% of its industry peers.
A Quick Ratio of 7.34 indicates that BNTX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.34, BNTX is doing good in the industry, outperforming 67.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.45
Quick Ratio 7.34
BNTX Yearly Current Assets VS Current LiabilitesBNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for BNTX have decreased strongly by -780.85% in the last year.
Looking at the last year, BNTX shows a very negative growth in Revenue. The Revenue has decreased by -27.96% in the last year.
The Revenue has been growing by 90.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-780.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.06%
Revenue 1Y (TTM)-27.96%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%-2.56%

3.2 Future

The Earnings Per Share is expected to grow by 9.18% on average over the next years. This is quite good.
BNTX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.23% yearly.
EPS Next Y-92.43%
EPS Next 2Y-41.48%
EPS Next 3Y-22.99%
EPS Next 5Y9.18%
Revenue Next Year-23.44%
Revenue Next 2Y-9.43%
Revenue Next 3Y-6.34%
Revenue Next 5Y4.23%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BNTX Yearly Revenue VS EstimatesBNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
BNTX Yearly EPS VS EstimatesBNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTX Price Earnings VS Forward Price EarningsBNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTX Per share dataBNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

A cheap valuation may be justified as BNTX's earnings are expected to decrease with -22.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.48%
EPS Next 3Y-22.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BNTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONTECH SE-ADR

NASDAQ:BNTX (6/13/2025, 8:00:02 PM)

After market: 106.57 0 (0%)

106.57

+1.65 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners22.49%
Inst Owner Change2.4%
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap25.62B
Analysts80
Price Target134.75 (26.44%)
Short Float %6%
Short Ratio4.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)188.14%
Min EPS beat(2)150.91%
Max EPS beat(2)225.36%
EPS beat(4)2
Avg EPS beat(4)73.79%
Min EPS beat(4)-62.82%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)298.37%
EPS beat(12)8
Avg EPS beat(12)207.85%
EPS beat(16)12
Avg EPS beat(16)165.24%
Revenue beat(2)2
Avg Revenue beat(2)57.27%
Min Revenue beat(2)6.92%
Max Revenue beat(2)107.62%
Revenue beat(4)2
Avg Revenue beat(4)11.13%
Min Revenue beat(4)-56.98%
Max Revenue beat(4)107.62%
Revenue beat(8)2
Avg Revenue beat(8)-8.3%
Revenue beat(12)5
Avg Revenue beat(12)2.28%
Revenue beat(16)9
Avg Revenue beat(16)11.05%
PT rev (1m)-2.56%
PT rev (3m)-5.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-55.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4%
Revenue NY rev (1m)-0.77%
Revenue NY rev (3m)-21.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.09
P/FCF N/A
P/OCF 107.14
P/B 1.15
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)-3.68
EYN/A
EPS(NY)-6.41
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)0.99
OCFY0.93%
SpS13.17
BVpS92.96
TBVpS87.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.95%
ROE -3.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.9%
FCFM N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 151.78%
Cap/Sales 16.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.45
Quick Ratio 7.34
Altman-Z 6.29
F-Score3
WACC7.13%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-780.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.06%
EPS Next Y-92.43%
EPS Next 2Y-41.48%
EPS Next 3Y-22.99%
EPS Next 5Y9.18%
Revenue 1Y (TTM)-27.96%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%-2.56%
Revenue Next Year-23.44%
Revenue Next 2Y-9.43%
Revenue Next 3Y-6.34%
Revenue Next 5Y4.23%
EBIT growth 1Y-232.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.91%
EBIT Next 3Y-7.6%
EBIT Next 5Y22.18%
FCF growth 1Y-105.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.13%
OCF growth 3Y-38.43%
OCF growth 5YN/A